Autoimmune disorder with antiphospholipid antibodies causing arterial/venous thrombosis and pregnancy morbidity.
Also known as: APS, antiphospholipid syndrome, Hughes syndrome, lupus anticoagulant, anticardiolipin
Try two board-style Antiphospholipid Syndrome questions
Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.
Question 1HematologyMedium
A 35-year-old female with presumed antiphospholipid antibody syndrome (APS) based on a single positive anticardiolipin IgG has her second deep vein thrombosis (DVT) while on warfarin (INR 2.1). She has no known triple-positive APS. Which of the following is the most appropriate next step?
- ASwitch to apixaban
- BPlace an inferior vena cava filter
- CAdd clopidogrel to current warfarin
- DIncrease warfarin target INR to 4.5-5.0
- EConfirm persistent APS antibody status
Reveal answer & full explanation
Correct answer: E — Confirm persistent APS antibody status
- ASwitch to apixaban
- BPlace an inferior vena cava filter
- CAdd clopidogrel to current warfarin
- DIncrease warfarin target INR to 4.5-5.0
- EConfirm persistent APS antibody status✓
Why Confirm persistent APS antibody status is correct
- A single positive anticardiolipin IgG may be transient; antiphospholipid syndrome (APS) diagnosis requires two positive tests at least 12 weeks apart
- Before escalating anticoagulation, confirm persistent APS antibody positivity to ensure the diagnosis is truly established
- Also evaluate warfarin adherence and drug interactions that may have caused a low INR at the time of the thrombotic event
Why the others are wrong
- Increase warfarin target INR to 4.5-5.0 — for confirmed APS with recurrent thrombosis despite therapeutic warfarin, the appropriate INR target increase is to 3.0-4.0 (not 4.5-5.0), or adding low-dose aspirin 81 mg; an INR target of 4.5-5.0 carries excessive bleeding risk
- Switch to apixaban — direct oral anticoagulants (DOACs) are not recommended for triple-positive APS (the TRAPS trial showed rivaroxaban was inferior to warfarin); DOACs should be used with extreme caution in APS generally and are not an appropriate escalation after recurrent thrombosis on therapeutic warfarin, where the options are raising the INR target to 3-4, adding low-dose aspirin, or switching to low-molecular-weight heparin
- Add clopidogrel to current warfarin — clopidogrel has no established role in APS; when escalation is warranted, the antiplatelet option is low-dose aspirin, and adding clopidogrel to warfarin mainly increases bleeding risk
- Place an inferior vena cava filter — a filter is tempting for a clot that recurred on anticoagulation, but IVC filters are reserved mainly for acute VTE when anticoagulation cannot be given; she can still be anticoagulated, a filter does nothing for the underlying hypercoagulable state and raises the long-term risk of recurrent DVT, and recurrence on warfarin calls for confirming the APS diagnosis and then intensifying antithrombotic therapy, not a filter
Question 2ReproductiveMedium
A 35-year-old woman with systemic lupus erythematosus and antiphospholipid syndrome (lupus anticoagulant positive on two occasions) presents at 8 weeks gestation after three consecutive first-trimester losses, all chromosomally normal. She is started on low-molecular-weight heparin plus low-dose aspirin for obstetric antiphospholipid syndrome. Which of the following best describes the expected effect of this regimen on her pregnancy outcome?
- ALive birth rate is unchanged compared with aspirin alone
- BLive birth rate remains below 20 percent despite therapy
- CLive birth rate improves to roughly 70 to 75 percent
- DLive birth rate approaches 95 percent with normalized risk
- ELive birth rate improves only if prednisone is added
Reveal answer & full explanation
Correct answer: C — Live birth rate improves to roughly 70 to 75 percent
- ALive birth rate is unchanged compared with aspirin alone
- BLive birth rate remains below 20 percent despite therapy
- CLive birth rate improves to roughly 70 to 75 percent✓
- DLive birth rate approaches 95 percent with normalized risk
- ELive birth rate improves only if prednisone is added
Why live birth rate improves to roughly 70 to 75 percent is correct
- This patient meets criteria for obstetric antiphospholipid syndrome (APS): recurrent early pregnancy loss with a persistently positive lupus anticoagulant.
- The standard treatment is combined low-molecular-weight heparin (LMWH) plus low-dose aspirin started early in pregnancy.
- This regimen reduces complement activation and anti-trophoblast antibody effects, improves placental implantation, and provides anticoagulation at the maternal-fetal interface.
- In landmark randomized data, LMWH plus aspirin raised the live birth rate to approximately 70 to 75 percent versus about 40 percent with aspirin alone.
Why the others are wrong
- Live birth rate remains below 20 percent despite therapy — this figure reflects the dismal untreated natural history of recurrent loss in APS, not the treated outcome.
- Live birth rate is unchanged compared with aspirin alone — incorrect; the addition of LMWH produces a clinically and statistically significant improvement over aspirin monotherapy.
- Live birth rate approaches 95 percent with normalized risk — overstates the benefit; therapy markedly reduces but does not eliminate the excess risk, and these pregnancies remain high-risk for later complications such as preeclampsia, growth restriction, and stillbirth, requiring close surveillance.
- Live birth rate improves only if prednisone is added — tempting in a patient with SLE, and prednisone plus aspirin was once used for antiphospholipid-related pregnancy loss; but glucocorticoids added maternal and fetal morbidity (preterm birth, hypertension, gestational diabetes) without improving live birth over heparin-based therapy, and LMWH plus low-dose aspirin achieves its benefit without them.
That's 2. Get 7,700+ more.
Unlock the full FirstPassPA bank: 7,700+ board-style questions, flashcards, and an AI tutor that explains every answer. Your 7-day free trial includes everything, and there's no credit card required.
Start your 7-day free trial →
🔒 Free preview limit reached
Keep reading — start your free trial
You've read your 2 free diagnosis previews. Create your free account to unlock the full Antiphospholipid Syndrome (APS) outline — plus all 514 diagnoses, 7,700+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Free to start · No credit card · Cancel anytime
Risk factors
- Systemic lupus erythematosus (30-40% have APL antibodies; ~10-15% develop APS)
- Other autoimmune diseases — Sjögren syndrome, RA, systemic sclerosis
- Infections (transient antibodies) — syphilis, HIV, HCV
- Drug-induced — chlorpromazine, procainamide, hydralazine
- Family history of autoimmune disease
Pathophysiology
Pathogenic autoantibodies, principally anti-β2-glycoprotein-1, bind phospholipid-protein complexes on endothelium, platelets, and trophoblasts. Activation of complement, endothelial cells, and platelets shifts hemostatic balance toward thrombosis. In pregnancy, placental thrombosis and direct trophoblast injury cause miscarriage, IUGR, and preeclampsia.
Clinical presentation
Symptoms
- DVT, PE — most common manifestation
- Arterial thrombosis — stroke (especially in young patients), TIA, MI, limb ischemia
- Recurrent pregnancy loss (≥3 consecutive losses <10 weeks), late fetal loss ≥10 weeks, severe preeclampsia, IUGR
- Livedo reticularis — net-like purple skin discoloration
- Thrombocytopenia (mild-moderate)
- Cardiac valve thickening or vegetations (Libman-Sacks endocarditis)
- Cognitive dysfunction, migraine, transverse myelitis (less common)
Signs / physical exam
- Livedo reticularis or livedo racemosa
- Cutaneous ulcers, digital ischemia
- Cardiac murmur from valve involvement
- Focal neurological deficits
Classic findings
Young patient with unprovoked venous or arterial thrombosis (DVT, PE, stroke) and/or recurrent pregnancy loss, often with livedo reticularis, mild thrombocytopenia, and a prolonged aPTT that does not correct on mixing study; antiphospholipid antibodies persist on repeat testing ≥12 weeks apart. Catastrophic APS is the rare variant: thrombosis in ≥3 organs developing within 1 week, with small-vessel occlusion on histology.
Differential diagnosis
- Hereditary thrombophilias — Family history, venous thrombosis predominant; negative APL antibodies on repeat testing
- Heparin-induced thrombocytopenia — Heparin exposure, platelet drop with thrombosis, positive anti-PF4 antibodies
- TTP / atypical HUS — Microangiopathic hemolytic anemia, schistocytes, low ADAMTS13 (TTP); responds to plasma exchange
- Catastrophic APS (CAPS) — Variant — multi-organ thrombosis within days, mortality >40%
- Malignancy-associated thrombosis — Occult cancer, often pancreatic, lung, GI
- Vasculitis — Constitutional symptoms, multi-system organ involvement, elevated inflammatory markers, characteristic biopsy
Diagnostic workup
Diagnostic criteria
Revised Sapporo (Sydney) criteria — requires ≥1 clinical criterion (vascular thrombosis or pregnancy morbidity) AND ≥1 laboratory criterion (LA, anti-cardiolipin, or anti-β2GP1) on two occasions at least 12 weeks apart. The 2023 ACR/EULAR classification criteria require an entry criterion (a positive aPL test within 3 years of an aPL-associated clinical criterion), then ≥3 weighted points from clinical domains AND ≥3 points from laboratory domains.
Labs
- Three core antiphospholipid antibody tests, all measured on TWO occasions ≥12 weeks apart:
- - Lupus anticoagulant (LA) — coagulation-based assay (dRVVT, aPTT-based)
- - Anti-cardiolipin IgG and IgM (medium-high titer)
- - Anti-β2-glycoprotein-1 IgG and IgM
- CBC — assess for thrombocytopenia
- Coagulation studies — prolonged aPTT that does not correct with mixing study suggests lupus anticoagulant
- ANA, anti-dsDNA, complement to evaluate for SLE
- Direct Coombs (may coexist with AIHA)
Imaging
- Duplex US, CTPA, MRI brain as clinically indicated by symptoms
- Echocardiogram to evaluate for Libman-Sacks endocarditis
Treatment
First-line
- Acute thrombosis — therapeutic anticoagulation: unfractionated heparin or LMWH bridge to warfarin (INR 2-3)
- Long-term venous thrombosis — warfarin INR 2-3 indefinitely
- Long-term arterial thrombosis or recurrent venous thrombosis on warfarin — warfarin INR 3-4, or warfarin + low-dose aspirin
- DOACs (rivaroxaban, apixaban) are INFERIOR to warfarin in triple-positive APS — avoid
Obstetric APS (pregnancy)
- Prophylactic LMWH (enoxaparin 40 mg daily) PLUS low-dose aspirin (81 mg)
- Therapeutic LMWH if prior thrombosis
- Continue 6 weeks postpartum
- Avoid warfarin throughout pregnancy (embryopathy at 6-12 weeks; fetal bleeding and CNS abnormalities later): switch to LMWH before 6 weeks' gestation; warfarin may be resumed postpartum and is compatible with breastfeeding; avoid DOACs
Catastrophic APS (CAPS)
- ICU-level care
- Triple therapy: anticoagulation (heparin) + high-dose glucocorticoids + plasma exchange and/or IVIG
- Rituximab or eculizumab for refractory cases
- Treat precipitating triggers (infection, surgery, drug withdrawal)
Asymptomatic antibody carriers
- Low-dose aspirin may be considered in high-risk profiles (triple-positive, SLE)
- Aggressive cardiovascular risk factor modification
- Avoid combined estrogen contraceptives
Second-line / adjunct
- Hydroxychloroquine — adjunctive, especially in SLE-associated APS
- Statins for vascular protection
- Rituximab or eculizumab for refractory/catastrophic disease
Complications
- Recurrent thrombosis despite anticoagulation
- Catastrophic APS (mortality 30-50%)
- Stroke and cumulative cognitive impairment
- Pregnancy loss, severe preeclampsia, HELLP
- Libman-Sacks endocarditis with embolic events
- Diffuse alveolar hemorrhage
- Adrenal hemorrhage and primary adrenal insufficiency
- Chronic kidney disease (APS nephropathy)
PANCE pearls
- Confirm any positive antiphospholipid test ≥12 weeks later — transient positivity occurs with infection.
- Triple-positive APS (LA + anti-cardiolipin + anti-β2GP1) confers highest thrombosis risk and warrants warfarin over DOACs (TRAPS trial).
- A prolonged aPTT that fails to correct on mixing study and corrects with added phospholipid suggests lupus anticoagulant.
- Warfarin INR target 2-3 for venous events; higher (or warfarin + ASA) for arterial events.
- Pregnant patients with APS should receive LMWH + aspirin, not warfarin (teratogen).
- Catastrophic APS is a life-threatening emergency — recognize and start triple therapy immediately.
References
- 2023 ACR/EULAR Criteria — Barbhaiya M et al. The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria. Arthritis Rheumatol 2023.
- TRAPS trial — Pengo V et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 2018; 132:1365-1371.
- Sapporo/Sydney criteria — Miyakis S et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 2006.